Annovis Bio, Inc. (ANVS) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17
	10-K	10-K	10-K	10-K	10-K	S-1/A
Revenues	0.0	0.0	0.0	0.0	0.1	0.3
Revenue growth				-100.0%	-59.2%
Cost of goods sold	0.0	0.0	0.0	0.0	0.7	0.5
Gross profit	0.0	0.0	0.0	0.0	-0.6	-0.3
Gross margin					-539.7%	-100.0%
Selling, general and administrative [+]	9.0	6.1	3.6	0.8	0.6	0.4
General and administrative	9.0	6.1	3.6	0.8	0.6	0.4
Research and development	16.5	8.5	3.1	0.8
Other operating expenses					-0.5
EBIT [+]	-25.5	-14.5	-6.6	-1.6	-0.7	-0.7
EBIT growth	75.5%	118.9%	313.6%	124.9%	4.6%
EBIT margin					-639.7%	-249.6%
Interest income, net [+]	0.2	0.0	0.0	0.0	0.0	0.0
Interest expense				0.0
Interest income	0.2	0.0	0.0		0.0	0.0
Other income (expense), net [+]		0.0	1.1	0.7
Unrealized gain/loss on derivatives			0.0	-0.1
Pre-tax income	-25.3	-14.5	-5.5	-1.0	-0.7	-0.7
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-25.3	-14.5	-5.5	-1.0	-0.7	-0.7
Net margin					-639.6%	-249.6%

Basic EPS [+]	($3.10)	($1.90)	($0.87)	($3.51)	($2.57)	($2.66)
Growth	63.4%	119.4%	-75.3%	36.3%	-3.5%
Diluted EPS [+]	($3.10)	($1.90)	($0.87)	($3.51)	($2.57)	($2.66)
Growth	63.4%	119.4%	-75.3%	36.3%	-3.5%

Shares outstanding (basic) [+]	8.2	7.6	6.3	0.3	0.3	0.3
Growth	7.0%	20.9%	2132.4%	1.8%	8.4%
Shares outstanding (diluted) [+]	8.2	7.6	6.3	0.3	0.3	0.3
Growth	7.0%	20.9%	2132.4%	1.8%	8.4%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.